11 December 2024
Hogan Lovells advises OncoVerity in securing extended Series A to advance Cusatuzumab in newly diagnosed acute myeloid leukemia
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Andrew Strong Lead | Hogan Lovells Cadwalader | Partner | M&A | Houston |
| Michael Frank Lead | Hogan Lovells Cadwalader | Partner | Tax, Pensions & Benefits | Silicon Valley |
| Josh Ling | Hogan Lovells Cadwalader | Associate | M&A | Houston |
| Leyla S. Gungor | Hogan Lovells Cadwalader | Other | Not stated | Washington, D.C. |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- OncoVerityIssuer
- Counterparties
- argenx (Investor)
RefinedScience (Investor)